Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for CUE-221 (Anti-IgE Antibody) in Chronic Spontaneous Urticaria. The expected timing is based on the latest available company guidance and may change.
05/14/26:- China Phase 2 CSU study data expected in H2 2026. 08/03/26:- IND submitted for CUE-221 in Food Allergy. Phase 2 CSU data readout expected by end of Q3 2026. 08/14/26:- Phase 2 CSU data is expected by the end of Q3 2026.
Verification
Confirm timing and program details against the company announcement or filing.